This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Drug form of traditional Chinese medicine compound found to improve survival of mice with brain tumors

Drug form of traditional Chinese medicine compound improved survival of mice with brain tumors
Graphical Abstract. Credit: Cell Reports Medicine (2023). DOI: 10.1016/j.xcrm.2023.101019

A new study shows how a drug made from a natural compound used in traditional Chinese medicine works against malignant brain tumors in mice, creating a promising avenue of research for glioblastoma treatment.

In the study, published in Cell Reports Medicine, researchers showed how a formulation of the compound, called indirubin, improved the survival of mice with . They also tested a new formulation that was easier to administer, taking the potential pharmaceutical approach one step closer to with human participants.

"The interesting thing about this drug is that it targets a number of important hallmarks of the disease," said Sean Lawler, lead author and a Brown University associate professor of pathology and laboratory medicine. "That's appealing because this type of keeps finding ways around individual mechanisms of attack. So if we use multiple mechanisms of attack at once, perhaps that will be more successful."

The research team included scientists from Brown's Legorreta Cancer Center and School of Engineering; the department of neurosurgery at Brigham and Women's Hospital/Harvard Medical School; and Phosphorex, Inc./Cytodigm, Inc.

Glioblastoma is the most common and aggressive type of brain cancer. The standard of care is chemotherapy, radiation and surgery, which may improve symptoms but don't cure or stop the cancer.

Indirubin is a natural product present in indigo plants and a constituent of the traditional Chinese medicine Dang Gui Long Hui Wan, which has been used in the treatment of chronic myelogenous leukemia, according to the researchers. Derivatives of the indirubin have shown potential for the treatment of cancer through a range of mechanisms.

Research published 10 years ago by Lawler and others showed that indirubin slowed the growth of glioblastoma tumors in mice. However, he said, the researchers weren't able to explain why. What's more, the modified drug wasn't very easy to work with, making it challenging for scientists to test dosage levels or efficiently deliver it to the tumor.

As the scientists continued to research the compound, they were contacted by the Massachusetts-based biomedical company Phosphorex, which develops technology to improve pharmaceutical formulations. Phosphorex had patented a formulation of indirubin, called 6'-bromoindirubin acetoxime (BiA), which made the compound easier to use as an injectable cancer treatment.

The researchers tested the nanoparticle formulation of BiA on glioblastoma tumors in , focusing on how the drug would affect the .

Not only did BiA slow the growth and proliferation of tumor cells (confirming the results of previous studies), but it also improved survival via effects on important immunotherapeutic targets.

"The drug impacted the immune system in these mouse experiments in a way that we think could enhance clinical immunotherapy in humans," explained Lawler, whose lab therapeutic approaches for the treatment of brain cancer.

The researchers will continue to test the to see how it interacts with chemotherapy and radiation, with the aim of developing clinical trials for participants with glioblastoma. While scientists have been studying glioblastoma for decades, Lawler said that there haven't been many significant therapeutic breakthroughs, until now.

"Over the past 20 years or so, there haven't been many findings of note that have really impacted survival in a meaningful way, so we are very eagerly looking for new approaches," Lawler said. "This research offers a new approach, and that's why we're so excited about it."

More information: Mykola Zdioruk et al, PPRX-1701, a nanoparticle formulation of 6′-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models, Cell Reports Medicine (2023). DOI: 10.1016/j.xcrm.2023.101019

Journal information: Cell Reports Medicine
Provided by Brown University
Citation: Drug form of traditional Chinese medicine compound found to improve survival of mice with brain tumors (2023, April 14) retrieved 18 May 2024 from https://medicalxpress.com/news/2023-04-drug-traditional-chinese-medicine-compound.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers demonstrate in mice a new way to deliver medication to malignant brain tumors

89 shares

Feedback to editors